Fenticonazole
Trade name: lomexin
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jul 20, 2020 (NCT06056947)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
Clc1ccc(C(Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1- Mol. weight
- 455.41 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1651990 ↗
- ChEMBLCHEMBL2107703 ↗
Also known as
- 1-(2,4-dichloro-beta-((p-(phenylthio)benzyl)oxy)phenethyl)imidazole
- fenizolan
- fenizolan
- fenticonazole
- fenticonazole
- fenticonazole
- fenticonazole
- fenticonazole
- fenticonazole mononitate
- fenticonazole mononitate
- fenticonazole nitrate
- fenticonazole nitrate
- fenticonazole nitrate
- fenticonazole nitrate
- gynoxin
- gynoxin
- laurimic
- lomexin
- lomexin
- lomexin
- lomexin
- micofulvin
- rec 15-1476
- rec 15/1476
- rec 15/1476
- terlomexin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05361369 | Phase 1 | May 9, 2022 | Exeltis, MonitorCRO |
| NCT06056947 | Phase 3 | Jul 20, 2020 | Ege University, Exeltis, MonitorCRO |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exeltis | For profit | 2 | 1 | 2 | 2020 |
| MonitorCRO | For profit | 2 | 0 | 2 | 2020 |
| Ege University | Academic/Hospital | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1